Latest
News

Edinburgh: May 2018

NuCana Reports First Quarter 2018 Financial Results

Edinburgh: May 2018

NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors

Edinburgh: May 2018

NuCana CEO Hugh Griffith Honoured with the Outstanding Achievement Award From Life Sciences Scotland NuCana also awarded Investment of the Year at awards gala in Glasgow.

Past Releases

New York: May 2018

NuCana plc to participate in the Jefferies 2018 Global Healthcare Conference, Thursday 7 June 2018

Edinburgh: April 2018

NuCana plc Announces Appointment of Adam George to its Board of Directors

Edinburgh: March 2018

NuCana Reports Financial Results for the Year Ended December 31, 2017

Edinburgh: March 2018

NuCana to participate in the Cowen and Company 38th Annual Health Care Conference, Boston, MA

Edinburgh: January 2018

NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-line Treatment of Advanced Biliary Tract Cancer

Edinburgh: November 2017

NuCana plc to participate in the Evercore ISI Biopharma Catalyst / Deep Dive Conference

Edinburgh: November 2017

NuCana Announces First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer

Edinburgh: November 2017

NuCana plc Presented at the Jefferies 2017 London Healthcare Conference

Edinburgh: October 2017

NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs

Edinburgh: September 2017

NuCana plc Announces Pricing of Initial Public Offering

Edinburgh: September 2017

NuCana announces interim data from First-In-Human Study of transformative anti-cancer agent, NUC-3373 and received Best Poster Presentation Award at ESMO 2017

Edinburgh: September 2017

NuCana announces positive results of NUC-1031 (Acelarin®) in advanced ovarian cancer at ESMO 2017

Boston: March 2017

NuCana presented at the Cowen & Company 37th Annual Healthcare Conference, Boston, Tuesday 7th March 2017, 12.00-12.25pm

New York: February 2017

NuCana participated in the LEERINK Partners 6th Global Healthcare Conference, New York, NY, 15th and 16th February 2017

San Francisco: January 2017

Hugh S. Griffith, CEO presented at the 35th Annual J.P. Morgan Healthcare Conference, San Francisco, January 10th 2017.

Chicago: June 2016

NuCana’s Acelarin achieves high clinical activity and durable disease control in patients with recurrent ovarian cancer

Edinburgh: March 2016

NuCana’s Chief Scientific Officer, Professor Chris McGuigan

Boston: November 2015

NuCana presents exciting data on novel anticancer agent, NUC-3373, at the AACR-NCI-EORTC conference in Boston.

Edinburgh: July 2015

NuCana appoints Professor Chris McGuigan as Chief Scientific Officer.

Chicago: May 2015

NuCana presents ground-breaking final results of the first in human Phase I/II study with Acelarin in advanced solid tumours at the ASCO 51st Annual Meeting.

Chicago: May 2015

Acelarin achieves very high disease control rates in patients with advanced gynaecological cancers in a Phase I/II setting. Study results presented at the ASCO 51st Annual Meeting.

Philadelphia: April 2015

NuCana presents data on the Molecular Diagnostics programme for Acelarin at the AACR Annual Meeting.

Edinburgh: December 2014

NuCana appoints Dr. Paolo Paoletti to its board of Directors.

Chicago: May 2014

Acelarin achieves high disease control rate in patients with advanced cancer.ProGem1 study results presented at the ASCO 50th Annual Meeting.

Edinburgh: April 2014

NuCana announces a Series B financing of $57 million to fund expansion of clinical studies with its anti-cancer ProTides.

San Diego: April 2014

NuCana presents exceptional data for anti-cancer agent, Acelarin, at the AACR Annual Meeting.

San Diego: March 2014

NuCana to present at AACR in San Diego, April 2014.

Edinburgh: February 2014

Important Results of NuCana’s lead ProTide published in prominent scientific journal.

Edinburgh: September 2013

NuCana to attend ESMO 2013 in Amsterdam on 27th September 2013.

Edinburgh: July 2013

NuCana highlight EvaluatePharma report valuing the industries pipeline products. ProTide technology takes number one position.

Cardiff: June 2013

'Drug hunter' Chris McGuigan on NuCana and medical research excitement.

Chicago: June 2013

Encouraging results from the ProGem1 study of Acelarin (NUC-1031) in patients with advanced cancer presented at ASCO 2013.

Edinburgh: May 2013

NuCana to present Phase I clinical data at ASCO 2013 in Chicago on 3rd June 2013.

Edinburgh: April 2013

NuCana Invited to Present at BioEquity Europe on Wednesday 22nd May 2013.

Edinburgh: April 2013

NuCana Appoints Erwan Lejeune as Scientific Affairs Manager.

Edinburgh: March 2013

NuCana to Present at BioTrinity on Wednesday 15th May 2013

Edinburgh: February 2013

NuCana Ups and Downs of a Drug Hunter - from the Lab to Patients.

A lecture by Prof. Chris McGuigan as part of the 'Science in Health' public lecture series at Cardiff University.

Edinburgh: February 2013

NuCana - Pioneering pair invest in a healthy future.

Edinburgh: February 2013

NuCana Biomed announced as joint winners of the Investment of the Year (2012) Award.

Edinburgh: February 2013

NuCana joint winners of the Investment of the Year (2012) Award, download the press release.

Edinburgh: May 2012

NuCana announces the appointment of Ian Abercrombie as Chief Operating Officer.

Edinburgh: November 2011

NuCana secures $10.4 million Series A Financing to accelerate it's ProTide Anti-Cancer Drugs into Clinical Development.

International: November 2011

NuCana Gets $10.5M for ProTide Cancer Drugs.

Scotland: November 2011

Life Science specialists £6.7m for new venture.

Wales: November 2011

Welsh scientists could prevent cancer cells becoming resistant to drugs.

Edinburgh: February 2011

NuCana announced it had completed a further equity financing that will enable NuCana's first product to enter clinical development.

Edinburgh: February 2011

Hugh Griffth to be the Keynote Speaker at the prestigious Scottish Enterprise Life Sciences Annual Dinner on 3rd February 2011.

Cardiff: January 2011

Chris Wood to present at Cardiff University EPSRC/PRESIDENTS ENTREPRENEURSHIP DAY on "Discovering New Medicines & Making Money".

Edinburgh: December 2010

NuCana announces the appointment of Martin Mellish as Non Executive Director to the Board of Directors.

Edinburgh: June 2010

Hugh Griffith guest speaker at BIA & Ernst & Young 'Beyond Borders' Seminar.

Edinburgh: May 2010

Hugh Griffith provides vision for challenges facing Biotechnology in the foreword to Marks & Clerk Life Sciences Report 2010.

Cardiff: April 2010

Christopher Wood to present at Wales Cancer Conference in Cardiff, 14th - 15th April 2010.

Edinburgh: February 2010

Hugh Griffith to present at BIA Scotland BioLeadership Forum and Dinner, 4th February 2010.

Edinburgh: December 2009

NuCana Completes Financing to Expand Anti-Cancer Drug Development Programme.

Edinburgh: December 2009

Alida Capital International Completes Financing into NuCana BioMed.

Cardiff: November 2009

Morvus Technology and NuCana sign exclusive world-wide licence to develop ProTide Technology in Cancer.

"Read all about it..."

The Scotsman Newspaper logo

NuCana collect two awards at 2018 Scottish Life Science Awards.......

The winners of 2018’s prestigious Scottish Life Sciences Awards were announced yesterday in a ceremony in Glasgow attended by many of the industry’s leading players.

750 people attended the event in Glasgow Hilton last night - marking a return to the city for the first in over ten years as innovators in the burgeoning sector were rewarded.

Read More

In The Media

The Scotsman: April 2018

NuCana plc wins in two catergories at the Scottish Life Science Awards 2018

The Herald: September 2017

Scots firm behind pioneering cancer treatments floats for £75 million

BQ2: October 2016

Scotland Special Report

Labiotech: June 2016

12 European Biotechs which “stole the show” at World most Important Cancer Meeting

Scrip: July 2015

ProTide man Chris McGuigan hopes to make NuCana the next Gilead.

Bioworld Today: June 2015

NuCana set to follow “groundbreaking” ASCO data with phase III trial.

NuCana readies suite of phase III cancer trials after rounding up mid-phase data.

ASCO: May 2015

Watch Professor Sarah Blagden talk about Acelarin at the ASCO (American Society of Clinical Oncology) 51st Annual Meeting.

Financial Times: September 2014

Europe struggles to catch US biotech bulls.

BioCentury: April 2014

Sofinnova Ventures led NuCana BioMed Ltd.’s $57 million B round.

BioWorld: April 2014

High tide for protides: Nucana Biomed pulls in $57M series B.

BBC News - Scotland Business: April 2014

Funding boost for life sciences firm NuCana BioMed.

Venturewire: April 2014

Sofinnova Ventures Leads $57M Financing for NuCana BioMed.

Edinburgh: February 2013

NuCana joint winners of the Investment of the Year (2012) Award, watch NuCana's short film of the award ceremony.

What's happening...

The Scotsman Newspaper logo

New York: May 2018

NuCana plc to participate in the Jefferies 2018 Global Healthcare Conference, Thursday 7 June 2018

Read More

Past Events

New York: May 2018

NuCana plc participated in the William Blair Late-Stage Therapeutics Conference, 3 May 2018

Boston: March 2018

NuCana plc participated in the Cowen & Company 38th Annual Healthcare Conference, 12-14th March 2018

San Francisco: January 2018

NuCana presented promising clinical data at ASCO GI on NUC-1031 (Acelarin®) as front-line treatment of Advanced Biliary Tract Cancer

London: November 2017

NuCana plc presented at the Jefferies 2017 London Healthcare Conference, London, Wednesday 15th November 2017

Boston: March 2017

NuCana presented at the Cowen & Company 37th Annual Healthcare Conference, Boston, Tuesday 7th March 2017

New York: February 2017

NuCana participated in the LEERINK Partners 6th Global Healthcare Conference, New York, NY, 15th and 16th February 2017

San Francisco: January 2017

Hugh S. Griffith, CEO presented at the 35th Annual J.P. Morgan Healthcare Conference, San Francisco, January 10th 2017

Tokyo: October 2016

Hugh S. Griffith, CEO of NuCana, presented at the 9th annual Japan Biopharma Partnering Conference in Tokyo, 25 October 2016

Boston: September 2016

Hugh S. Griffith, CEO of NuCana, presented at Citi's 11th annual Biotech Conference in Boston, 8 September 2016

Chicago: June 2016

NuCana presented at the American Society of Clinical Oncology in Chicago, 6 June 2016

New Orleans: April 2016

NuCana presented at the American Association for Cancer Research Conference in New Orleans, 16 April 2016

New York: April 2016

NuCana presented at the Needham Healthcare Conference in New York, 12 April 2016

Edinburgh: March 2016

NuCana presented at Scotsman Life Sciences Conference in Edinburgh, 1 March 2016

New York: February 2016

NuCana presented at Leerink Partners Global Healthcare Conference in New York, 10 February 2016

San Francisco: January 2016

Hugh S. Griffith, CEO of NuCana, presented at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, 13 January 2016

New York: December 2015

NuCana’s CEO, Hugh S. Griffith, presented at the 27th annual Piper Jaffray Healthcare Conference in New York, 2 December 2015

Boston: November 2015

NuCana presented NUC-3373 data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, 7 November 2015

Tokyo: October 2015

Hugh S. Griffith, NuCana’s CEO, presented at Japan Biopharma Partnering Conference in Tokyo, 27 October 2015

Cardiff: September 2015

Hugh S. Griffith presented at Tenovus Cancer Care & Life Sciences Research Network Wales Conference at the Life Sciences Hub in Cardiff Bay, 15 September 2015

Chicago: May 2015

NuCana presented results from Acelarin Phase I/II study at the 51st Annual Meeting of the American Society of Clinical Oncology in Chicago, 30 May 2015

Philadelphia: April 2015

NuCana presented Acelarin molecular profiling data at the American Association for Cancer Research Annual Meeting in Philadelphia,
21 April 2015

New York: March 2015

Hugh S. Griffith, NuCana’s CEO, presented at JMP Securities Life Sciences Conference in New York, 27 March 2015

Edinburgh: January 2015

Hugh S. Griffith, NuCana’s CEO, interviewed by BBC, 26 January 2015